Inmune Bio (INMB) Other Non-Current Liabilities (2021 - 2023)

Inmune Bio (INMB) posted Other Non-Current Liabilities of $804000.0 for Q3 2023, up 46.18% sequentially from $550000.0 in Q4 2022.

Inmune Bio (INMB) Other Non-Current Liabilities (2021 - 2023) Analysis & Trends

Inmune Bio has reported Other Non-Current Liabilities for 3 years, with the latest figure at $804000.0 in Q3 2023.

Quarterly Other Non-Current Liabilities changed N/A year-over-year to $804000.0 in Q3 2023, while the trailing twelve-month figure through Sep 2023 was $804000.0 (changed N/A YoY) and the FY2022 annual result came in at $550000.0, changed N/A from the prior year.
Other Non-Current Liabilities climbed to $804000.0 in Q3 2023 per INMB's latest filing, from $550000.0 in the prior quarter.
Over five years, Other Non-Current Liabilities peaked at $804000.0 in Q3 2023 and troughed at $160000.0 in Q2 2021.
A 3-year average of $439500.0 and a median of $397000.0 in 2021 frame the typical range for Other Non-Current Liabilities.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Vertex Pharmaceuticals	139.13 Bn	131.28 Bn	2.84 Bn
2	Regeneron Pharmaceuticals	85.77 Bn	77.77 Bn	3.93 Bn
3	Argenx Se	64.64 Bn	59.46 Bn	1.37 Bn
4	Moderna	58.29 Bn	53.16 Bn	52.00 Mn
5	BeOne Medicines	41.92 Bn	36.82 Bn	1.53 Bn
6	Alnylam Pharmaceuticals	31.58 Bn	28.28 Bn	992.69 Mn
7	BioNTech SE	28.12 Bn	9.73 Bn	668.28 Mn
8	Insmed	27.39 Bn	26.22 Bn	358.27 Mn
9	Royalty Pharma	27.27 Bn	26.43 Bn	-
10	Inmune Bio	61.59 Mn	43.18 Mn	-

Download Data